Could a cancer pill ease rare, painful skin diseases?
NCT ID NCT06545695
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether low doses of erlotinib, a drug originally used for cancer, can improve symptoms of rare genetic skin conditions called keratinopathies. About 44 adults with confirmed diagnoses will take increasing doses over 24 weeks. The goal is to see if it reduces skin thickening, scaling, and pain, while keeping side effects manageable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Erlotinib (a cancer drug used at lower doses)
What this could lead to
If it works, this could point toward a treatment for rare, painful skin conditions that currently have few options.
What could go wrong
This is a very early, small trial (44 people) testing a drug that can cause side effects like rash and stomach issues. It may not work for all types of keratinopathy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALMOPLANTAR KERATODERMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Dermatology, Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States